Concentration of Management Resources in a Single Pharmaceutical Segment
First written in FY2016. 17 of 18 entries say "Restated". Latest entry: FY2024-Q1.
10 other companies' latest entry also says "Restated".
- FY2024-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed. - FY2023RestatedAnnual report
「The Group operates by concentrating management resources in a single pharmaceutical business segment comprising research and development, procurement, manufacturing and sales. Accordingly, disclosure by reportable segment has been omitted.」
The concentration of management resources in the pharmaceutical business and the single-segment structure have been reconfirmed. - FY2023-Q3RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed in the segment information. - FY2023-Q2RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed. - FY2023-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The business structure of concentrating management resources from research and development through sales in the single pharmaceutical business segment has been reconfirmed in the segment information. - FY2022-Q3RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed. - FY2022-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed in the segment information. - FY2021-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The structure of concentrating management resources from research and development through sales in the single pharmaceutical business segment has been reconfirmed in the segment information. - FY2020-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed. - FY2019-Q3RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed. - FY2019-Q1RestatedAnnual report
「As the Group operates in a single pharmaceutical business segment, disclosure by segment has been omitted.」
The single-segment structure of the pharmaceutical business has also been reconfirmed in the discussion of operating results. - FY2018RestatedAnnual report
「As the Group operates in a single pharmaceutical business segment, disclosure of segment information has been omitted.」
The business structure of concentrating management resources in the single pharmaceutical business segment has been reconfirmed. - FY2018-Q3RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed in the segment information. - FY2018-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed in the segment information. - FY2017RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group concentrates its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The single-segment structure that concentrates management resources on the pharmaceutical business, from research and development through manufacturing and sales, has been reconfirmed. - FY2017-Q2RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group conducts its business by concentrating its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs. Accordingly, information by reportable segment is omitted.」
The structure of concentrating management resources from research and development through sales in the single pharmaceutical business segment has been reconfirmed. - FY2017-Q1RestatedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group concentrates its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The structure of concentrating management resources in the single pharmaceutical business segment has been reconfirmed in the segment information. - FY2016First statedAnnual report
「Under the corporate philosophy “For the human fight against disease and suffering,” our group concentrates its management resources on the single Pharmaceuticals segment, covering research and development, procurement, manufacturing and sales, with the aim of creating innovative new drugs that truly benefit patients and address unmet medical needs.」
The Company has a single-segment structure that concentrates management resources on its pharmaceutical business, from research and development through manufacturing and sales.